DK3099800T3 - Ekspression og oprensning af crm197 og beslægtede proteiner - Google Patents
Ekspression og oprensning af crm197 og beslægtede proteiner Download PDFInfo
- Publication number
- DK3099800T3 DK3099800T3 DK15743243.6T DK15743243T DK3099800T3 DK 3099800 T3 DK3099800 T3 DK 3099800T3 DK 15743243 T DK15743243 T DK 15743243T DK 3099800 T3 DK3099800 T3 DK 3099800T3
- Authority
- DK
- Denmark
- Prior art keywords
- crm197
- purification
- expression
- related proteins
- proteins
- Prior art date
Links
- 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 238000000746 purification Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0051—Oxidoreductases (1.) acting on a sulfur group of donors (1.8)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2511/00—Cells for large scale production
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2523/00—Culture process characterised by temperature
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/34—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Corynebacterium (G)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Analytical Chemistry (AREA)
- Epidemiology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Computational Biology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461934377P | 2014-01-31 | 2014-01-31 | |
| PCT/US2015/014130 WO2015117093A1 (en) | 2014-01-31 | 2015-02-02 | Expression and purification of crm197 and related proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3099800T3 true DK3099800T3 (da) | 2021-01-11 |
Family
ID=53757814
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15743243.6T DK3099800T3 (da) | 2014-01-31 | 2015-02-02 | Ekspression og oprensning af crm197 og beslægtede proteiner |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10093704B2 (da) |
| EP (1) | EP3099800B1 (da) |
| JP (2) | JP2017510290A (da) |
| KR (1) | KR102282930B1 (da) |
| CN (1) | CN106661587B (da) |
| AU (1) | AU2015210674B2 (da) |
| CA (1) | CA2938251C (da) |
| DK (1) | DK3099800T3 (da) |
| NZ (1) | NZ722504A (da) |
| WO (1) | WO2015117093A1 (da) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10597664B2 (en) * | 2014-01-31 | 2020-03-24 | Fina Biosolutions, Llc | Expression and purification of CRM proteins and related proteins, and protein domains |
| DK3099800T3 (da) * | 2014-01-31 | 2021-01-11 | Fina Biosolutions Llc | Ekspression og oprensning af crm197 og beslægtede proteiner |
| CN106350527B (zh) * | 2016-11-03 | 2019-05-07 | 中国人民解放军军事医学科学院生物工程研究所 | 一种可在大肠杆菌可溶性高表达的白喉毒素突变体 |
| CN110366428B (zh) | 2016-12-30 | 2024-05-17 | Vaxcyte公司 | 具有非天然氨基酸的多肽-抗原缀合物 |
| US11951165B2 (en) | 2016-12-30 | 2024-04-09 | Vaxcyte, Inc. | Conjugated vaccine carrier proteins |
| KR101908590B1 (ko) | 2017-02-01 | 2018-10-16 | (주)포바이오코리아 | Crm197의 용해성 단백질 발현 및 정제 방법 |
| EP3444269A1 (en) | 2017-08-17 | 2019-02-20 | National Research Council of Canada | Systems and methods for the production of diphtheria toxin polypeptides |
| CN107365782A (zh) * | 2017-08-29 | 2017-11-21 | 廊坊梅花生物技术开发有限公司 | 一种基因工程菌及其应用 |
| WO2020010016A1 (en) | 2018-07-04 | 2020-01-09 | Sutrovax, Inc. | Self-adjuvanted immunogenic conjugates |
| DK3817775T3 (da) | 2018-07-04 | 2024-09-16 | Vaxcyte Inc | Forbedringer i immunogene konjugater |
| WO2020010000A1 (en) | 2018-07-04 | 2020-01-09 | Sutrovax, Inc. | Improved methods for the preparation of immunogenic conjugates |
| ES2944837T3 (es) | 2018-11-08 | 2023-06-26 | Sutro Biopharma Inc | Cepas de E. coli con citoplasma oxidativo |
| CN110452838B (zh) * | 2019-07-18 | 2020-12-29 | 艾美卫信生物药业(浙江)有限公司 | 一种crm197菌种培养基、配制方法及发酵培养方法 |
| KR102949308B1 (ko) * | 2020-03-16 | 2026-04-06 | 피나 바이오솔루션스, 엘엘씨 | 용해성 재조합 단백질의 생산 |
| US12351850B2 (en) | 2020-04-30 | 2025-07-08 | Sutro Biopharma, Inc. | Methods of producing full-length antibodies using E. coli |
| CN118027189B (zh) * | 2024-04-11 | 2024-12-06 | 上海惠盾因泰生物科技有限公司 | 一种抗白喉毒素突变体抗体及crm197的纯化制备方法和应用 |
| WO2026034998A1 (ko) * | 2024-08-07 | 2026-02-12 | 한국생명공학연구원 | 대장균 내 이황화 단백질의 폴딩 강화 방법 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE280235T1 (de) | 1993-03-05 | 2004-11-15 | Wyeth Corp | Plasmid zur herstellung von crm-protein und diphtherie-toxin |
| US5849301A (en) | 1993-09-22 | 1998-12-15 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Producing immunogenic constructs using soluable carbohydrates activated via organic cyanylating reagents |
| WO1995008348A1 (en) | 1993-09-22 | 1995-03-30 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Method of activating soluble carbohydrate using novel cyanylating reagents for the production of immunogenic constructs |
| DE19937218A1 (de) | 1999-08-06 | 2001-02-08 | Aventis Behring Gmbh | Verfahren zur Reindarstellung der den Blutgerinnungsfaktor VII aktivierenden Protease, ihres Proenzyms oder eines Gemisches beider Proteine mittels Affinitätschromatographie |
| US6872563B1 (en) | 1999-10-05 | 2005-03-29 | President And Fellows Of Harvard College | Compositions and methods for production of disulfide bond containing proteins in host cells |
| US7468275B2 (en) * | 2000-01-28 | 2008-12-23 | The Scripps Research Institute | Synthetic internal ribosome entry sites and methods of identifying same |
| WO2007063129A2 (en) | 2005-12-02 | 2007-06-07 | Novozymes A/S | Insolation of peptides , polypeptides and proteins |
| US7816117B2 (en) * | 2006-04-26 | 2010-10-19 | President And Fellows Of Harvard College | Prokaryotic host cells for expressing proteins rich in disulfide bonds |
| CN101265288B (zh) | 2007-03-13 | 2012-03-21 | 齐鲁制药有限公司 | Crm197突变体的纯化方法 |
| IT1398927B1 (it) * | 2009-06-25 | 2013-03-28 | Consorzio Interuniversitario Per Lo Sviluppo Dei Sistemi A Grande Interfase Csgi | Espressione batterica di un gene artificiale per la produzione di crm197 e derivati. |
| GB0917647D0 (en) | 2009-10-08 | 2009-11-25 | Glaxosmithkline Biolog Sa | Expression system |
| AU2010201410B2 (en) | 2010-03-30 | 2015-04-30 | Pelican Technology Holdings, Inc. | High level expression of recombinant CRM197 |
| KR20130072201A (ko) * | 2010-03-30 | 2013-07-01 | 피페넥스 인크. | 재조합 독소 단백질의 고수준 발현 |
| EP2560738B8 (en) | 2010-04-23 | 2019-09-25 | Serum Institute of India Private Limited | Simple method for simultaneous removal of multiple impurities from culture supernatants to ultralow levels |
| FR2988393B1 (fr) * | 2012-03-20 | 2014-05-09 | Commissariat Energie Atomique | Inhibiteur de l'hb-egf derive du domaine r de la toxine diphterique pour le traitement des maladies associees a l'activation de la voie hb-egf/egfr |
| GB201209896D0 (en) * | 2012-06-01 | 2012-07-18 | Fujifilm Diosynth Biotechnologies Uk Ltd | Process |
| US20150184215A1 (en) * | 2013-12-27 | 2015-07-02 | Development Center For Biotechnology | Development of the soluble recombinant crm197 production by e. coli |
| DK3099800T3 (da) * | 2014-01-31 | 2021-01-11 | Fina Biosolutions Llc | Ekspression og oprensning af crm197 og beslægtede proteiner |
-
2015
- 2015-02-02 DK DK15743243.6T patent/DK3099800T3/da active
- 2015-02-02 AU AU2015210674A patent/AU2015210674B2/en active Active
- 2015-02-02 US US15/114,642 patent/US10093704B2/en active Active
- 2015-02-02 WO PCT/US2015/014130 patent/WO2015117093A1/en not_active Ceased
- 2015-02-02 CA CA2938251A patent/CA2938251C/en active Active
- 2015-02-02 KR KR1020167023611A patent/KR102282930B1/ko active Active
- 2015-02-02 EP EP15743243.6A patent/EP3099800B1/en active Active
- 2015-02-02 CN CN201580018271.2A patent/CN106661587B/zh active Active
- 2015-02-02 NZ NZ722504A patent/NZ722504A/en unknown
- 2015-02-02 JP JP2016567466A patent/JP2017510290A/ja active Pending
-
2019
- 2019-07-10 JP JP2019128165A patent/JP7073312B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| NZ722504A (en) | 2017-08-25 |
| EP3099800B1 (en) | 2020-10-14 |
| JP7073312B2 (ja) | 2022-05-23 |
| US20160333057A1 (en) | 2016-11-17 |
| KR20160113276A (ko) | 2016-09-28 |
| JP2019205446A (ja) | 2019-12-05 |
| KR102282930B1 (ko) | 2021-07-27 |
| EP3099800A1 (en) | 2016-12-07 |
| WO2015117093A1 (en) | 2015-08-06 |
| US10093704B2 (en) | 2018-10-09 |
| AU2015210674B2 (en) | 2017-08-24 |
| AU2015210674A1 (en) | 2016-08-18 |
| CN106661587A (zh) | 2017-05-10 |
| CA2938251A1 (en) | 2015-08-06 |
| EP3099800A4 (en) | 2017-11-08 |
| CA2938251C (en) | 2021-01-12 |
| CN106661587B (zh) | 2020-01-24 |
| JP2017510290A (ja) | 2017-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3099800T3 (da) | Ekspression og oprensning af crm197 og beslægtede proteiner | |
| DK3653221T3 (da) | Anti-pvrig-antistoffer og anvendelsesfremgangsmåder | |
| DK3390444T3 (da) | Anti-tl1a-antigenbindende proteiner og anvendelser deraf | |
| DK3353210T3 (da) | Anti-TIGIT-antistoffer og fremgangsmåder til anvendelse | |
| DK3988117T3 (da) | Terapeutiske antistoffer og deres anvendelser | |
| DK3201336T3 (da) | Fremgangsmåder til ekstrahering og oprensning af ikke-denaturerede proteiner | |
| DK3215532T3 (da) | Anti-TIM3-antistoffer og fremgangsmåder til anvendelse | |
| DK3134530T3 (da) | Behandling af hyperbilirubinæmi | |
| DK3158054T3 (da) | Genetisk modificerede bakterier og fremgangsmåder til genetisk modifikation af bakterier | |
| DK3333191T3 (da) | Anti-C10ORF54-antistoffer og anvendelser deraf | |
| DK3137169T3 (da) | Hæmmere af lysin-specifik demethylase-1 | |
| DK3160956T3 (da) | Inhibitorer af lysin-specifik demethylase-1 | |
| DK3126388T3 (da) | Anti-EGFRvIII-antistoffer og anvendelser deraf | |
| DK3102673T3 (da) | Fremgangsmåder og sammensætninger til behandling af beta-talassæmi | |
| DK3102576T3 (da) | Dihydropyrrolopyridininhibitorer af ror-gamma | |
| DK3218358T3 (da) | Ifluorometyl-aminopyridiner og difluorometyl-aminopyrimidiner | |
| DK3288553T3 (da) | Kombinationer af cannabinoider og n-acylethanolaminer | |
| DK3511319T3 (da) | Hæmmere af lysinspecifik demethylase-1 | |
| DK3498292T3 (da) | Uspa2-proteinkonstruktioner og anvendelser deraf | |
| DK3368655T3 (da) | Forbedret proteinekspression og fremgangsmåder dertil | |
| IL272851A (en) | Methods of using dipivefrin | |
| DK3166628T3 (da) | Terapeutisk anvendelse af knoglemorfogenetiske proteiner | |
| DK3215493T3 (da) | Syntese af copanlisib og dihydrochloridsalt deraf | |
| DK3100050T3 (da) | Immobiliserede proteiner og anvendelse deraf | |
| DK3389669T3 (da) | Triterpensaponinvarianter, syntesefremgangsmåder og anvendelse deraf |